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COST OF ILLNESS OF ASHTMA IN A HOSPITAL OF A COLOMBIAN 
REGION 2006–2009
Hinestrosa F1, Martinez JA1, Díaz JA2
1Grünenthal Colombiana S.A, Bogota D.C, Colombia, 2Universidad Nacional de Colombia, 
Bogota, Colombia
OBJECTIVES: Estimate the disease burden and cost generating components of asthma 
from a health institution perspective in a region of Colombia. METHODS: This was 
a descriptive, retrospective, prevalence based study which included 2179 clinical charts 
from patients between children and adults from 2006 to 2009 in a region of Colombia. 
Direct costs for hospital care, medication and sick beneﬁt were taken from clinical 
charts, indirect costs arising from rehabilitation and premature death and early retire-
ment were estimated using the human capital approach (HCA) and friction costs 
method (FCM). RESULTS: Total costs for asthma, including direct and indirect costs, 
were calculated at 850.000 American dollars. CONCLUSIONS: There is room for 
substantial savings in the Colombian hospital, with indirect costs amounting to 74.8% 
of total costs and payment of sick beneﬁts through the sickness funds amounting to 
58.3% of indirect costs. These results gives a descriptive diagnosis which can be used 
to implement cost containing policies in the Colombian hospitals, costs may be 
reduced with better asthma control in patients.
PRS5
COST-EFFECTIVENESS OF PHARMACOLOGICAL INTERVENTIONS FOR 
SMOKING CESSATION: CURRENT EVIDENCE AND POLICY 
IMPLICATIONS
Heredia I, Valencia A, Bertozzi S
National Institute of Public Health, Cuernavaca, Morelos, Mexico
OBJECTIVES: A variety of pharmaceutical treatments for smoking cessation are now 
available. We conduct a systematic review on economic evaluations of these therapies 
between 2000–2007, ranked them by cost and effectiveness, and showed study limita-
tions in the process of deﬁning efﬁcient public policies. METHODS: A systematic 
search was conducted. PubMed (U.S. National Library of Medicine) and the NHS 
Economic Evaluation Database from the Centre for Reviews and Dissemination were 
reviewed in detail using standard criteria. RESULTS: Out of 870 relevant publications, 
49 complied with the inclusion criteria. The documents were very heterogeneous in 
terms of the following elements: perspective, methodology and effectiveness measures 
used; included costs; evaluated interventions, and studied population. The cost per life 
year gained, adjusted or not for quality, ranged between US$367 and US$7284 
(December 2006). In most of them, bupropion (with or without medical advice) was 
the most cost-effective option. Its incremental cost per life year gained, adjusted 
or not for quality, ranged from US$454 to US$2984 (December 2006). However, 
recent articles compared varenicline with bupropion and the nicotine patch and 
showed varenicline to be the most cost-effective. Nevertheless, additional evaluations 
of varenicline, including relapse rates over longer periods of time, are needed. CON-
CLUSIONS: Useful literature regarding the economic implications and health beneﬁts 
of pharmacotherapy for smoking cessation is available. The results suggest that phar-
macotherapy could be cost-effective in middle-income countries. Nevertheless, the lack 
of cost-effectiveness data from low- and middle-income countries cries out for more 
analyses that deal with the way in which the estimates change when models attempt 
to reproduce poorer settings. In addition, to obtain more robust estimates, it will be 
necessary to develop models that better predict the success of pharmacotherapy, 
incorporating adherence to therapy under non-controlled conditions, and the relation-
ship between the smokers’ behavior and the probability of cessation.
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COST-EFFECTIVENESS OF FLUTICASONE PROPIONATE/SALMETEROL 
(500/50 MG) IN THE TREATMENT OF COPD IN BRAZILIAN PUBLIC 
SECTOR
Bueno RLP1, Godoy MR2
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OBJECTIVES: To determine the cost-effectiveness ratio for ﬂuticasone/salmeterol 
combination in the treatment of Chronic Obstructive Pulmonary Disease—COPD, in 
Brazilian public sector. METHODS: A cost-effectiveness analysis from the public 
payer perspective, with a time horizon of 5 years was conduct. A decision tree with 
a Markov chain considering the probabilities of increasing, decreasing or maintaining 
disease severity through four health states, three of them based on FEV1 from moder-
ate to very severe according to American Thoracic Society (ATS) guidelines were per-
formed. Study comparators examined were usual care (UC), long-acting anticholinergic 
drug, tiotropium (TIO) and ﬂuticasone/salmeterol (SERETIDE®). The clinical aspects 
regarding beneﬁts (exacerbations rates) and probabilities of transition data were 
extract from head to head randomized clinical trials for the alternatives. Treatment 
costs including maintenance costs on each stage of disease and moderate or severe 
exacerbations were collected from public payer reimbursement list and drugs costs 
were collected from Price Indexes—BPS or manufactures price list. The discounting 
rate was 5% for costs and beneﬁts, the results were converted in US Dollars using a 
rate of R$2.3/USD 1.00. A one-way sensitivity analysis was performed. RESULTS: 
Patients using ﬂuticasone/salmeterol or tiotropium get more beneﬁts compared with 
usual care (TIO  6.75; SERETIDE®  6.82 versus 7.61 exacerbation in 5 years), and 
usual care remains the lowest total cost per treatment (UC  USD1,519; SERETIDE® 
 US$3025 and TIO US$ 4840). The CE ratios were US$200; US$1904 and US$1649 
for UC; SERETIDE® and TIO, respectively. The sensitivity analysis on efﬁciency and 
costs of ﬂuticasone/salmeterol results show sensitivity to the price of tiotropium. 
CONCLUSIONS: SERETIDE® is a cost-effective therapy for low level of willingness 
to pay; it offers the protection against exacerbations at low cost compared with TIO. 
Results are sensitive to TIO’s price, showing the need of public policies to assure the 
best resource allocation.
SENSORY SYSTEMS DISORDERS – Cost Studies
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COSTO-EFECTIVIDAD DEL USO DE ETANERCEPT VS LOS 
ANTICUERPOS MONOCLONALES ANTI-TNF EN PACIENTES CON 
PSORIASIS EN PLACAS EN MÉXICO
Aguirre A1, García E1, Bierschwale H1, Ramirez BA2
1Wyeth México, Naucalpan, Mexico, 2Hospital Regional 25 IMSS, México D.F, Mexico
OBJECTIVOS: Determinar la razón de costo-efectividad incremental (RCEI) de etan-
ercept versus los anticuerpos monoclonales anti-TNF en el tratamiento de pacientes 
con Psoriasis en placas (PsO) tomando como base una perspectiva institucional en 
México. METODOLOGÍAS: Se desarrolló un modelo de análisis de decisión para 
comparar la razón de costo-efectividad de etanercept (50 mg dos veces por semana 
durante las primeras 12 semanas y después 50 mg por semana) versus adalimumab 
(40mg cada dos semanas) e inﬂiximab (5mg/Kg semana 0, 2, 6 y después cada 8 
semanas) en pacientes bajo tratamiento de PsO con una respuesta inadecuada a terapia 
sistémica o fototerapia. Tomando como base el precio unitario de cada biológico, se 
estimó el costo anual de tratamiento. Considerando una tasa de respuesta de al menos 
75 de acuerdo al Índice de Área de Psoriasis y Severidad (PASI 75) de acuerdo 
a lo reportado en la literatura, se estimó la razón de costo-efectividad incremental. 
RESULTADOS: El costo anual de tratamiento con etanercept, adalimumab e inﬂix-
imab por paciente fue de $173,597, $171,971 y $217,536 pesos mexicanos respec-
tivamente. Las tasas de respuesta PASI 75 de etanercept, adalimumab e inﬂiximab 
publicadas en la literatura cientíﬁca son 63%, 56% y 61% respectivamente. La RCEI 
por paciente adicional que alcanza una respuesta PASI 75 con etanercept en compara-
ción con adalimumab fue de $34,654 y de $2,196,960 comparando etanercept con 
inﬂiximab. CONCLUSIONES: El uso de etanercept en pacientes con PsO en una 
alternativa costo-efectiva en comparación con adalimumab al tomar como umbral de 
costo-efectividad el PIB per cápita sugerido por la Organización Mundial de la Salud, 
y costo-ahorradora al comparar etanercept con inﬂiximab. Si se incrementará el uso 
de etanercept una mayor cantidad de pacientes tendrían acceso al tratamiento con 
terapias biológicas y las instituciones de salud podrían contener costos en el trata-
miento de la PsO en México.
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A COMPREHENSIVE SYSTEMATIC REVIEW OF THE PSYCHOMETRIC 
PROPERTIES OF VFQ-25 IN GLAUCOMA
Ejzykowicz F1, Gwadry-Sridhar F2
1University of Southern California, Los Angeles, CA, USA, 2University of Western Ontario, 
London, ON, Canada
Glaucoma can create visual impairment with ongoing morbidity. Having an instru-
ment that assesses the progression of diseases of the eye and assesses treatment is 
necessary due to increased prevalence. OBJECTIVES: Evaluate the psychometric prop-
erties (reliability, validity, responsiveness, and interpretability) of a short form of 
vision-speciﬁc instrument VFQ-25 for glaucoma and other eye chronic diseases., 
Compare the VFQ-25 to the generic SF-36. METHODS: We conducted an extensive 
literature review using Medline, OVID, Google Scholar, Cochrane Library, ARVO 
and ISOQOL databases from the years 2000 to 2007. We included all articles that 
addressed the psychometric properties of VFQ-25. If no psychometric properties were 
assessed, we excluded the article RESULTS: 8 articles and 2 abstracts relating to 
VFQ-25 met the inclusion criteria. Internal consistency reliability (Cronbach’s alpha 
0.70) was high for most of all subscales, except driving. Ceiling scores were observed 
in all studies included in this systematic review. However, no ﬂoor effect was detected. 
Discriminant and convergent validity were different for a few subscales (driving, social 
function and ocular pain), for others they ranged from 86%-100%. Scale-scale corre-
lations between general health and other subscales were low (0.3). In contrast, global 
score is moderately to highly correlated with other subscales (0.5–0.9). Compared to 
SF-36, VFQ-25 was low correlated. Responsiveness of VFQ-25 was not measured 
in patients with glaucoma. The effect sizes were small to moderate (0.07–0.51). 
CONCLUSIONS: The results suggest that VFQ-25 is a reliable and valid measure of 
health-related quality of life in glaucoma patients and other chronic eye diseases. 
However, longitudinal studies should be done to assess responsiveness and interpret-
ability of the questionnaire. Our ﬁndings suggest that VFQ-25 and SF-36 are capturing 
different dimensions of health.
